We found that SIRT1 serum levels did not statistically significantly differ between MS patients and control group subjects in males (0.102 (0.028) ng/mL vs. 2.291 (4.095) ng/mL, p < 0.001) (Figure 3). This evidence concerns the gene SIRT1 and myeloid sarcoma.